Izinkomba, Izinzuzo kanye Nemiphumela Yokwelapha
I-Phosphodiesterase-4-inhibitors (PDE4) efana neDaliresp (i-roflumilast) iyisigaba esisha sezidakamizwa ze- chronic obstructive pulmonary disease (COPD ) nezinye izifo zamaphaphu. Lezi zidakamizwa zisebenza ukuvimbela ukuvuvukala emoyeni kubantu abangamelana nokuphathwa okujwayelekile. I-Daliresp (i-roflumilast) yiyona kuphela i-PDE4 inhibitor elamukelwe manje e-United States.
Indlela i-Phosphodiesterase-4-Inhibitors esebenza ngayo
Imithi enjengeDaliresp umsebenzi ngokuvimbela imiphumela ye-phosphodiesterase 4, i-enzyme esebenza ukudiliza i-molecule ebizwa ngokuthi i-cyclic adenosine monophosphate (cAMP.) Ukwanda okwenziwe emampeni (ngoba kungaphuliwe yi-phosphodiesterase 4) kwenza ukunciphisa ukuvutha amaphaphu phakathi kwezinye izinto.
Okuphawulekayo kwe-COPD ukuvuvukala okungapheli, futhi abantu abane-COPD kanye ne-asthma bavame ukukhiqizwa ngokweqile kwe-PDE4 okufaka isandla kulokhu ukuvuvukala.
Ngokunciphisa ukuvuvukala, imithi efana noDaliresp inganciphisa ukukhishwa kwe-mucus ngokweqile kwe-COPD, nokunciphisa ukulungiswa kwamanqamu.
Yini eyenziwa yi-PDE4 Inhibitors?
Ngokwandisa amazinga e -AMP kanye nokwehla kwesibindi, ama-inhibitors e-PDE4 anganciphisa inani lezinkinga ze-COPD futhi athuthukise ukusebenza kwamapayipi. Ngokukhula kwe -AMP, bangase babangele ezinye ze-bronchodilation.
Kubalulekile ukuqaphela ukuthi lezi zidakamizwa azilungisi amaphaphu, zisebenza esikhundleni sokuncipha ukuvuvukala futhi zivimbele umonakalo owengeziwe nokukhushulwa kwezimpawu.
Imibandela lapho kungenzeka khona uDaliresp (Roflumilast)
Izimo okungenzeka ukuthi uDaliresp zingasetshenziswa zihlanganisa:
- I-COPD
- I-asthma
- I-Psoriasis
- I-arthritis yengqondo
Zisetshenziswa Nini?
I-PDE4 inhibitors njengoDaliresp isetshenziselwa ukuthuthukisa umsebenzi wamaphaphu kubantu abane-COPD esimile abangamelana nokuphathwa okujwayelekile.
Nge-COPD kubonakala sengathi inenzuzo kakhulu kubantu abane- bronchitis engapheli abanokukhubazeka kaningi kwesifo sabo .
Njengoba lezi zidakamizwa zisebenza ukuvuvukala okungapheli, azisetshenziselwa ukuhlaselwa okunamandla kwe-COPD noma i-asthma, kodwa kunokuba kube nokugcinwa okungapheli kwesifo.
Ngokungafani ne-bronchodilators engatholakali, i-Daliresp iyimithi yokwelashwa yodwa kanye yansuku zonke etholakale ekuthuthukiseni umsebenzi wamaphaphu eziguli eziphathwe nge- salmeterol ne- Spiriva (tiotropium.)
Imiphumela ye-PDE4 inhibitors ibonakala iyengezwa nge-corticosteroids.
Okuqhamuka uma udla imishanguzo
Imiphumela emibi kakhulu ye-PDE4 inhibitors ihlanganisa isifo sohudo, isicashu, kanye nekhanda. Kungabangela ukulahlekelwa isisindo, ngakho isisindo kufanele sihlolwe ngesikhathi sokwelashwa futhi sibangele izimpawu ezingokwengqondo kwabanye abantu.
Ukusebenzisana
Ngenxa yemetabolism yayo yi-cytochrome P-450, i-PDE4 inhibitors ingase iphazamise (ukwandisa noma yehle) nezinye izidakamizwa nazo zenziwe ngendlela enjalo, isibonelo, imithi efana ne-erythromycin, i-cimetidine, amaphilisi okulawula ukubeletha, imithi yokwelapha eminye, nokuningi.
Futhi ebizwa ngokuthi : PDE4, i-phosphodiesterase-4 inhibitors ekhethiwe
Imithombo:
UFerguson, G., no B. Yenza. Ukuphathwa kwezifo ezinomsoco ezingavimbayo zokuphefumula. Kusesikhathini. Kubuyekezwe 01/21/16.
Mulhall, A., Droege, C., Ernst, N., Panos, R., noMnu Zafar. I-Phosphodiesterase 4 inhibitors ekwelapheni isifo esingenasifo se-pulmonary chronic obstructive: ukubuyekezwa kwezidakamizwa zamanje nezithuthukayo. I-Expert Opinion on Izidakamizwa Zokuphenya . 2015. 24 (12): 1597-611.
Reid, D., no-N. Pham. I-Roflumilast: ukwelashwa kwinoveli ye-chronic obstructive pulmonary disease. Annals of Pharmacotherapy. 2012. 46 (4): 521-9.
Ilabhulali Kazwelonke Yezokwelapha yase-US. I-MedlinePlus. I-Roflumilast. Kubuyekezwe 08/15/12. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a611034.html